Copenhagen and Oslo, 2012-09-03 18:00 CEST (GLOBE NEWSWIRE) --
Affitech has today received a major shareholder notification from Trans Nova Investments Ltd., who in accordance with Section 28a of the Danish Securities Trading Act, notifies, on behalf of Alexander Shuster, Chairman of the Board of Directors of Affitech A/S, of the following transactions:
| Name | Trans Nova Investments Limited |
| Reason for reporting | Related party to Alexander Shuster, Chairman of the Board of Affitech A/S |
| Issuer and ISIN | Affitech A/S/DK0015966592 |
| Type of transaction | Purchase of shares |
| Date of transaction | 31st August, 2012 |
| Relevant market | NASDAQ OMX COPENHAGEN A/S |
| Number of traded securities and market value | 25,075,235 shares. Market value DKK 5,015,047 |
| Number of traded securities and market value | 408,853 shares. Market value DKK 75,760.46 |
About Affitech
Affitech A/S is a publicly traded (NASDAQ OMX Copenhagen) human therapeutic antibody company based in Copenhagen, Denmark with R&D facilities in Oslo, Norway. The company utilizes a range of proprietary antibody technologies for the discovery of fully human antibodies for application in oncology, inflammation and other disease areas. CBAS™ (Cell Based Antibody Selection) is Affitech’s premier discovery engine for the isolation of lead antibodies to cell surface molecules in situ. Several of the Company's proprietary product candidates were generated by CBAS™. Further information is available at www.affitech.com.
Contact
Randi Krogsgaard, Director IR & Communications
Tel # +45 2320 1001, e-mail: ir@affitech.com
